Neil J Weissman

List of Publications by Year in Descending Order

237 papers	29,579 citations	68 h-index	170 g-index
248 ext. papers	34,379 ext. citations	7.8 avg, IF	6.34 L-index

#	Paper	IF	Citations
237	Optical coherence tomography in coronary atherosclerosis assessment and intervention.. *Nature Reviews Cardiology*, **2022**,	14.8	8
236	Right Ventricular-Pulmonary Arterial Coupling in Patients With HF Secondary MR: Analysis From the COAPT Trial. *JACC: Cardiovascular Interventions*, **2021**, 14, 2231-2242	5	6
235	3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. *Journal of the American College of Cardiology*, **2021**, 77, 1029-1040	15.1	36
234	Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes: A Secondary Analysis of the COAPT Trial. *JAMA Cardiology*, **2021**, 6, 427-436	16.2	14
233	Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial. *Circulation: Cardiovascular Interventions*, **2021**, 14, e010300	6	7
232	Effect of Mitral Valve Gradient After MitraClip on Outcomes in Secondary Mitral Regurgitation: Results From the COAPT Trial. *JACC: Cardiovascular Interventions*, **2021**, 14, 879-889	5	5
231	Doppler Velocity Index Outcomes Following Surgical or Transcatheter Aortic Valve Replacement in the PARTNER Trials. *JACC: Cardiovascular Interventions*, **2021**, 14, 1594-1606	5	0
230	Prosthesis-Patient Mismatch After Aortic Valve Replacement in the PARTNER 2 Trial and Registry. *JACC: Cardiovascular Interventions*, **2021**, 14, 1466-1477	5	4
229	Outcomes of transcatheter mitral valve repair for secondary mitral regurgitation by severity of left ventricular dysfunction. *EuroIntervention*, **2021**, 17, e335-e342	3.1	6
228	Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure: COAPT Trial. *JACC: Heart Failure*, **2021**, 9, 559-567	7.9	0
227	Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure: COAPT Trial. *Circulation*, **2021**, 144, 426-437	16.7	12
226	Left Ventricular Global Longitudinal Strain as a Predictor of Outcomes in Patients with Heart Failure with Secondary Mitral Regurgitation: The COAPT Trial. *Journal of the American Society of Echocardiography*, **2021**, 34, 955-965	5.8	0
225	Diastolic Function and Clinical Outcomes After Transcatheter Aortic Valve Replacement: PARTNER 2 SAPIEN 3 Registry. *Journal of the American College of Cardiology*, **2020**, 76, 2940-2951	15.1	5
224	Reply: Disproportionate Secondary Mitral Regurgitation: An Exciting Hypothesis Still in Need of Actual Data. *Journal of the American College of Cardiology*, **2020**, 75, 2096-2097	15.1	
223	Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries. *Journal of the American College of Cardiology*, **2020**, 75, 2446-2458	15.1	26
222	Left Ventricular Hypertrophy and Clinical Outcomes Over 5 Years After TAVR: An Analysis of the PARTNER Trials and Registries. *JACC: Cardiovascular Interventions*, **2020**, 13, 1329-1339	5	13
221	Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial. *Journal of the American College of Cardiology*, **2020**, 76, 1830-1843	15.1	40

220	NYHA Functional Classification and Outcomes After Transcatheter Mitral Valve Repair in Heart Failure: The COAPT Trial. *JACC: Cardiovascular Interventions*, **2020**, 13, 2317-2328	5	11
219	Outcome of Flow-Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: An Analysis of the PARTNER 2 Trial and Registry. *Circulation: Cardiovascular Interventions*, **2020**, 13, e008792	6	7
218	Pulmonary Hypertension in Transcatheter Mitral Valve Repair for Secondary Mitral Regurgitation: The COAPT Trial. *Journal of the American College of Cardiology*, **2020**, 76, 2595-2606	15.1	9
217	Impact of Tricuspid Regurgitation on Clinical Outcomes: The COAPT Trial. *Journal of the American College of Cardiology*, **2020**, 76, 1305-1314	15.1	20
216	The fallacy of indexed effective orifice area charts to predict prosthesis-patient mismatch after prosthesis implantation. *European Heart Journal Cardiovascular Imaging*, **2020**, 21, 1116-1122	4.1	8
215	Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation: The COAPT Trial. *Journal of the American College of Cardiology*, **2019**, 74, 2969-2979	15.1	88
214	2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) and the American Society of Echocardiography. *Circulation: Cardiovascular Imaging*, **2019**, 12, e000027	3.9	15
213	Comprehensive Echocardiographic Assessment of Normal Transcatheter Valve Function. *JACC: Cardiovascular Imaging*, **2019**, 12, 25-34	8.4	62
212	2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Transthoracic Echocardiography) and the American Society of Echocardiography. *Journal of the American Society of Echocardiography*, **2019**, 32, 1161-1248	5.8	4
211	2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) and the American Society of Echocardiography and the American College of Cardiology. *Journal of the American College of Cardiology*, **2019**, 74, 403-469	15.1	12
210	Guidelines for the Evaluation of Valvular Regurgitation After Percutaneous Valve Repair or Replacement: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Angiography and Interventions, Japanese Society of Echocardiography, and Society for Cardiovascular Magnetic Resonance. *Journal of the American Society of Echocardiography*, **2019**, 32, 431-475	5.8	145
209	Implications of Left Ventricular Geometry in Low-Flow Aortic Stenosis: A PARTNER 2 Trial Subanalysis. *JACC: Cardiovascular Imaging*, **2019**, 12, 367-368	8.4	2
208	Prospective US investigational device exemption trial of a sutureless aortic bioprosthesis: One-year outcomes. *Journal of Thoracic and Cardiovascular Surgery*, **2019**, 157, 1773-1782.e3	1.5	11
207	One-Year Outcomes After MitraClip for Functional Mitral Regurgitation. *Circulation*, **2019**, 139, 37-47	16.7	56
206	Hemodynamic and Echocardiographic Comparison of the Lotus and CoreValve Transcatheter Aortic Valves in Patients With High and Extreme Surgical Risk: An Analysis From the REPRISE III Randomized Controlled Trial. *Circulation*, **2018**, 137, 2557-2567	16.7	13
205	Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis. *European Heart Journal*, **2018**, 39, 1224-1245	9.5	18
204	Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. *American Heart Journal*, **2018**, 205, 1-11	4.9	55
203	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. *New England Journal of Medicine*, **2018**, 379, 1107-1117	59.2	143

202	The Effect of Post-Dilatation on Outcomes in the PARTNER 2 SAPIEN 3 Registry. *JACC: Cardiovascular Interventions*, **2018**, 11, 1710-1718	5	10
201	Transcatheter Mitral-Valve Repair in Patients with Heart Failure. *New England Journal of Medicine*, **2018**, 379, 2307-2318	59.2	1160
200	Use of Imaging Endpoints in Clinical Trials. *JACC: Cardiovascular Imaging*, **2017**, 10, 296-303	8.4	9
199	Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis: An Expert Statement. *Journal of the American College of Cardiology*, **2017**, 69, 2067-2087	15.1	60
198	Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. *Journal of the American Society of Echocardiography*, **2017**, 30, 303-371	5.8	1331
197	Longitudinal Hemodynamics of Transcatheter and Surgical Aortic Valves in the PARTNER Trial. *JAMA Cardiology*, **2017**, 2, 1197-1206	16.2	54
196	Association of Paravalvular Regurgitation With 1-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve. *JAMA Cardiology*, **2017**, 2, 1208-1216	16.2	89
195	Blood Pressure and Arterial Load After Transcatheter Aortic Valve Replacement for Aortic Stenosis. *Circulation: Cardiovascular Imaging*, **2017**, 10,	3.9	30
194	CT-Defined Prosthesis-Patient Mismatch Downgrades Frequency and Severity, and Demonstrates No Association With Adverse Outcomes After Transcatheter Aortic Valve Replacement. *JACC: Cardiovascular Interventions*, **2017**, 10, 1578-1587	5	24
193	Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials. *Obesity*, **2017**, 25, 39-44	8	12
192	Long-Term Valve Performance of TAVR and SAVR: A Report From the PARTNER I Trial. *JACC: Cardiovascular Imaging*, **2016**,	8.4	58
191	One-Year Clinical Outcomes With SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Severe Aortic Stenosis. *Circulation*, **2016**, 134, 130-40	16.7	136
190	The Need for Standardized Methods for Measuring the Aorta: Multimodality Core Lab Experience From the GenTAC Registry. *JACC: Cardiovascular Imaging*, **2016**, 9, 219-26	8.4	38
189	Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. *Lancet, The*, **2016**, 387, 2218-25	40	697
188	Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. *European Heart Journal*, **2016**, 37, 2252-62	9.5	247
187	The Future of Cardiac Imaging: Report of a Think Tank Convened by the American College of Cardiology. *JACC: Cardiovascular Imaging*, **2016**, 9, 1211-1223	8.4	24
186	Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. *JACC: Cardiovascular Imaging*, **2015**, 8, 340-360	8.4	173
185	A Summary of the American Society of Echocardiography Foundation Value-Based Healthcare: Summit 2014: The Role of Cardiovascular Ultrasound in the New Paradigm. *Journal of the American Society of Echocardiography*, **2015**, 28, 755-69	5.8	10

184	Evaluation of renal function before and after percutaneous mitral valve repair. *Circulation: Cardiovascular Interventions*, **2015**, 8,	6	30
183	Assessment of paravalvular aortic regurgitation after transcatheter aortic valve replacement: intra-core laboratory variability. *Journal of the American Society of Echocardiography*, **2015**, 28, 415-22	5.8	50
182	Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. *New England Journal of Medicine*, **2015**, 373, 2015-24	59.2	627
181	Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. *European Heart Journal*, **2015**, 36, 449-56	9.5	292
180	Fatty acids linked to cardiovascular mortality are associated with risk factors. *International Journal of Circumpolar Health*, **2015**, 74, 28055	1.7	36
179	Hemodynamic outcomes of transcatheter aortic valve replacement and medical management in severe, inoperable aortic stenosis: a longitudinal echocardiographic study of cohort B of the PARTNER trial. *Journal of the American Society of Echocardiography*, **2015**, 28, 210-7.e1-9	5.8	33
178	Thirty-day VARC-2 and performance data of a new self-expanding transcatheter aortic heart valve. *EuroIntervention*, **2015**, 11, 785-92	3.1	4
177	Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER trial cohort--a analysis. *Journal of the American College of Cardiology*, **2014**, 64, 1323-34	15.1	224
176	Intravascular ultrasound evidence of perivascular trauma during routine percutaneous coronary intervention. *International Journal of Cardiovascular Imaging*, **2014**, 30, 849-56	2.5	6
175	Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated with decreased hospitalizations. *JACC: Cardiovascular Interventions*, **2014**, 7, 662-73	5	97
174	Sex-related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis: Insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). *Journal of the American College of Cardiology*, **2014**, 63, 1522-8	15.1	111
173	Stenting for ST-segment elevation myocardial infarction is associated with less neointimal hyperplasia in the pooled IVUS analysis from HORIZONS-AMI and the TAXUS IV and V and ATLAS workhorse, long lesion, and direct stent studies. *Coronary Artery Disease*, **2014**, 25, 575-81	1.4	2
172	American Society of Echocardiography Cardiovascular Technology and Research Summit: a roadmap for 2020. *Journal of the American Society of Echocardiography*, **2013**, 26, 325-38	5.8	23
171	Implementation of echocardiography core laboratory best practices: a case study of the PARTNER I trial. *Journal of the American Society of Echocardiography*, **2013**, 26, 348-358.e3	5.8	72
170	Impact of lesion location on intravascular ultrasound findings and short-term and five-year long-term clinical outcome after percutaneous coronary intervention for saphenous vein graft lesions. *International Journal of Cardiology*, **2013**, 167, 29-33	3.2	7
169	Comparison of transcatheter and surgical aortic valve replacement in severe aortic stenosis: a longitudinal study of echocardiography parameters in cohort A of the PARTNER trial (placement of aortic transcatheter valves). *Journal of the American College of Cardiology*, **2013**, 61, 2514-21	15.1	181
168	Percutaneous mitral valve repair in the initial EVEREST cohort: evidence of reverse left ventricular remodeling. *Circulation: Cardiovascular Imaging*, **2013**, 6, 522-30	3.9	40
167	Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. *Circulation: Cardiovascular Imaging*, **2013**, 6, 560-7	3.9	57

166	Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy. *Circulation*, **2013**, 128, 1667-74	16.7	123
165	Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. *Obesity*, **2012**, 20, 1426-36	8	412
164	Mitroflow aortic bioprosthesis 5-year follow-up: north american prospective multicenter study. *Annals of Thoracic Surgery*, **2012**, 94, 1198-203	2.7	26
163	Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. *Journal of the American College of Cardiology*, **2012**, 59, 1058-72	15.1	1216
162	Intravascular ultrasound analysis of plaque characteristics and postpercutaneous coronary intervention catheterization outcomes according to the remodeling pattern in narrowed saphenous vein grafts. *American Journal of Cardiology*, **2012**, 110, 1290-5	3	5
161	Treatment of subacute and chronic thrombotic occlusions of lower extremity peripheral arteries with the excimer laser: a feasibility study. *Cardiovascular Revascularization Medicine*, **2012**, 13, 211-4	1.6	15
160	Intravascular ultrasound findings that are predictive of no reflow after percutaneous coronary intervention for saphenous vein graft disease. *American Journal of Cardiology*, **2012**, 109, 1576-81	3	19
159	Impact of drug-eluting stents on distal vessels. *Circulation: Cardiovascular Interventions*, **2012**, 5, 211-9	6	8
158	Quantitation of mitral regurgitation. *Circulation*, **2012**, 126, 2005-17	16.7	111
157	Edge effect from drug-eluting stents as assessed with serial intravascular ultrasound: a systematic review. *Circulation: Cardiovascular Interventions*, **2012**, 5, 305-11	6	13
156	Improved strut coverage and less late incomplete apposition with thin-strut TAXUS Liberté vs. TAXUS Express: the importance of stent platform design for drug-eluting stents. *Cardiovascular Revascularization Medicine*, **2011**, 12, 247-57	1.6	5
155	Dethrombosis of lower extremity thrombus by local delivery of thrombolysis using ClearWay transcatheter balloon irrigation: a feasibility study. *Cardiovascular Revascularization Medicine*, **2011**, 12, 350-4	1.6	12
154	A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 3067-77	5.6	433
153	The year in intracoronary imaging. *JACC: Cardiovascular Imaging*, **2010**, 3, 881-91	8.4	3
152	Cardiovascular disease prevalence and its relation to risk factors in Alaska Eskimos. *Nutrition, Metabolism and Cardiovascular Diseases*, **2010**, 20, 350-8	4.5	34
151	The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. *Journal of the American College of Cardiology*, **2010**, 55, 2721-6	15.1	174
150	Multicenter, placebo-controlled trial of lorcaserin for weight management. *New England Journal of Medicine*, **2010**, 363, 245-56	59.2	701
149	Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions. *American Journal of Cardiology*, **2010**, 105, 179-85	3	47

148	Effect of renal function on ultrasonic coronary plaque characteristics in patients with acute myocardial infarction. *American Journal of Cardiology*, **2010**, 105, 936-42	3	8
147	Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies. *JACC: Cardiovascular Interventions*, **2010**, 3, 486-94	5	57
146	Advances in intravascular imaging. *Circulation: Cardiovascular Interventions*, **2009**, 2, 482-90	6	64
145	An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. *American Journal of Cardiology*, **2009**, 103, 501-6	3	58
144	Relation of drug-eluting stent strut distribution to stent thrombosis in coronary arteries. *American Journal of Cardiology*, **2009**, 104, 343-8	3	4
143	Relation among lipoprotein subfractions and carotid atherosclerosis in Alaskan Eskimos (from the GOCADAN Study). *American Journal of Cardiology*, **2009**, 104, 1516-21	3	16
142	The predictive value of computed tomography calcium scores: a comparison with quantitative volumetric intravascular ultrasound. *Cardiovascular Revascularization Medicine*, **2009**, 10, 30-5	1.6	6
141	Intravascular ultrasound and 3D angle measurements of coronary bifurcations. *Catheterization and Cardiovascular Interventions*, **2009**, 73, 910-6	2.7	13
140	Attenuated plaque detected by intravascular ultrasound: clinical, angiographic, and morphologic features and post-percutaneous coronary intervention complications in patients with acute coronary syndromes. *JACC: Cardiovascular Interventions*, **2009**, 2, 65-72	5	98
139	Intravascular ultrasound: Virtual histology IVUS, integrated backscatter IVUS, and palpography. *Current Cardiovascular Imaging Reports*, **2009**, 2, 268-274	0.7	
138	Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. *JACC: Cardiovascular Interventions*, **2009**, 2, 312-20	5	140
137	TAXUS Liberté attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS program. *JACC: Cardiovascular Interventions*, **2009**, 2, 240-52	5	24
136	Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. *JACC: Cardiovascular Interventions*, **2009**, 2, 1269-75	5	143
135	Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the	5.8	887
134	Disease progression in nonintervened saphenous vein graft segments a serial intravascular ultrasound analysis. *Journal of the American College of Cardiology*, **2009**, 53, 1257-64	15.1	15
133	PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDY. *Journal of Clinical Lipidology*, **2009**, 3, 322-331	4.9	16
132	Extended-release niacin or ezetimibe and carotid intima-media thickness. *New England Journal of Medicine*, **2009**, 361, 2113-22	59.2	534
131	Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation. *Journal of the American Society of Echocardiography*, **2009**, 22, 755-65	5.8	142

130	Meta-analysis of the effects of paclitaxel-eluting stents versus bare metal stents on volumetric intravascular ultrasound in patients with versus without diabetes mellitus. *American Journal of Cardiology*, **2008**, 101, 1263-8	3	12
129	The virtual histology intravascular ultrasound appearance of newly placed drug-eluting stents. *American Journal of Cardiology*, **2008**, 102, 1182-6	3	18
128	Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. *American Journal of Cardiology*, **2008**, 102, 530-4	3	38
127	Impact of mild or moderate renal insufficiency on the intravascular ultrasonic analysis of chronic vascular response to paclitaxel-eluting and bare-metal stents (from the TAXUS IV, V, and VI trials). *American Journal of Cardiology*, **2008**, 102, 1009-16	3	3
126	ACCF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR 2008 appropriateness criteria for stress echocardiography: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, American Society of Echocardiography, American College of Emergency Physicians, American Heart Association, American Society of Nuclear Cardiology, Society for	15.1	147
125	Intravascular ultrasound findings in patients with restenosis of sirolimus- and paclitaxel-eluting stents. *International Journal of Cardiology*, **2008**, 125, 11-5	3.2	18
124	ACCF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR 2008 appropriateness criteria for stress echocardiography: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, American Society of Echocardiography, American College of Emergency Physicians, American Heart Association, American Society of Nuclear Cardiology, Society for	16.7	86
123	The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. *European Heart Journal*, **2008**, 29, 1851-7	9.5	241
122	Prevalence and correlates of subclinical atherosclerosis in Alaska Eskimos: the GOCADAN study. *Stroke*, **2008**, 39, 3079-82	6.7	12
121	Impact of in-stent minimal lumen area at 9 months poststent implantation on 3-year target lesion revascularization-free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI trials. *Circulation: Cardiovascular Interventions*, **2008**, 1, 111-8	6	14
120	No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 2243-8	5.6	23
119	Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. *JAMA - Journal of the American Medical Association*, **2008**, 299, 1678-89	27.4	185
118	ACCF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR 2008 Appropriateness Criteria for Stress Echocardiography. A report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, American Society of Echocardiography, American College of Emergency Physicians, American Heart Association, American Society of Nuclear Cardiology, Society for	2.7	3
117	Chronic arterial responses to overlapping paclitaxel-eluting stents: insights from serial intravascular ultrasound analyses in the TAXUS-V and -VI trials. *JACC: Cardiovascular Interventions*, **2008**, 1, 161-7	5	8
116	ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of	5.8	113
115	ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society	15.1	265
114	Intravascular ultrasonic study of gender differences in ruptured coronary plaque morphology and its associated clinical presentation. *American Journal of Cardiology*, **2007**, 100, 185-9	3	18
113	Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting stent deployment. *American Journal of Cardiology*, **2007**, 100, 615-20	3	133

112	Meta-analysis of angiographic versus intravascular ultrasound parameters of drug-eluting stent efficacy (from TAXUS IV, V, and VI). *American Journal of Cardiology*, **2007**, 100, 621-6	3	16
111	Peri-stent reference segment plaque burden is associated with disease progression in saphenous vein grafts (a serial intravascular ultrasound assessment). *American Journal of Cardiology*, **2007**, 100, 1233-8	3	1
110	Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. *European Heart Journal*, **2007**, 28, 1574-82	9.5	43
109	Intravascular Ultrasound: Principles and Clinical Applications **2007**, 152-171		
108	Comparison of ruptured plaques in native coronary arteries and in saphenous vein grafts: an intravascular ultrasound study. *American Journal of Cardiology*, **2006**, 97, 593-7	3	9
107	Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. *American Journal of Cardiology*, **2006**, 97, 823-9	3	121
106	An intravascular ultrasound analysis of the mechanisms of restenosis comparing drug-eluting stents with brachytherapy. *American Journal of Cardiology*, **2006**, 97, 1292-8	3	21
105	Frequency and severity of plaque prolapse within Cypher and Taxus stents as determined by sequential intravascular ultrasound analysis. *American Journal of Cardiology*, **2006**, 98, 1206-11	3	35
104	New imaging techniques for diagnosing coronary artery disease. *Cmaj*, **2006**, 174, 487-95	3.5	44
103	Plaque characterization with optical coherence tomography. *Journal of the American College of Cardiology*, **2006**, 47, C69-79	15.1	82
102	Negative remodeling and calcified plaque in octogenarians with acute myocardial infarction: an intravascular ultrasound analysis. *Journal of the American College of Cardiology*, **2006**, 47, 2413-9	15.1	47
101	Intravascular ultrasound in the drug-eluting stent era. *Journal of the American College of Cardiology*, **2006**, 48, 421-9	15.1	123
100	Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late "catch-up" phenomenon from ASPECT Study. *Journal of the American College of Cardiology*, **2006**, 48, 2432-9	15.1	90
99	Intravascular ultrasound assessment of the spatial distribution of ruptured coronary plaques in the left anterior descending coronary artery. *American Heart Journal*, **2006**, 151, 898-901	4.9	13
98	Comparison of paclitaxel-eluting stent and sirolimus-eluting stent expansion at incremental delivery pressures. *Cardiovascular Revascularization Medicine*, **2006**, 7, 208-11	1.6	20
97	Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. *Journal of Clinical Investigation*, **2006**, 116, 2510-20	15.9	327
96	Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: the Asian Pacific Multicenter Arthos Stent Study (PASS) trial. *American Heart Journal*, **2005**, 149, 336-41	4.9	17
95	Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. *Journal of the American College of Cardiology*, **2005**, 45, 1201-5	15.1	81

94	Incidence and clinical correlates of ruptured plaques in saphenous vein grafts: an intravascular ultrasound study. *Journal of the American College of Cardiology*, **2005**, 45, 1974-9	15.1	27
93	Comparison of quantitative angiographic parameters with the magnitude of neointimal hyperplasia measured by volumetric intravascular ultrasound in patients treated with bare metal and nonpolymeric paclitaxel-coated stents. *American Journal of Cardiology*, **2005**, 95, 105-7	3	5
92	Intravascular ultrasound assessment of neointima distribution and the length of stent that was free of intravascular ultrasound-detectable intimal hyperplasia in paclitaxel-eluting stents. *American Journal of Cardiology*, **2005**, 95, 107-9	3	15
91	Intravascular ultrasound stent area of sirolimus-eluting stents and its impact on late outcome. *American Journal of Cardiology*, **2005**, 95, 1240-2	3	12
90	Intravascular ultrasound assessment of ruptured atherosclerotic plaques in left main coronary arteries. *American Journal of Cardiology*, **2005**, 96, 794-8	3	16
89	Impact of renal function on coronary plaque morphology and morphometry in patients with chronic renal insufficiency as determined by intravascular ultrasound volumetric analysis. *American Journal of Cardiology*, **2005**, 96, 892-6	3	42
88	Serial intravascular ultrasound comparison of the extent and distribution of intimal hyperplasia six months after stent implantation for de novo versus in-stent restenosis lesions. *American Journal of Cardiology*, **2005**, 96, 897-900	3	8
87	Cardiovascular events in patients with coronary plaque rupture and nonsignificant stenosis. *American Journal of Cardiology*, **2005**, 96, 1631-5	3	10
86	Underexpansion of sirolimus-eluting stents: incidence and relationship to delivery pressure. *Catheterization and Cardiovascular Interventions*, **2005**, 65, 222-6	2.7	40
85	Relation of intimal hyperplasia thickness to stent size in paclitaxel-coated stents. *American Journal of Cardiology*, **2004**, 94, 196-8	3	7
84	Late thrombosis in cypher stents after the discontinuation of antiplatelet therapy. *Cardiovascular Radiation Medicine*, **2004**, 5, 173-6		15
83	The importance of gender on coronary artery size: in-vivo assessment by intravascular ultrasound. *Clinical Cardiology*, **2004**, 27, 291-4	3.3	39
82	American Society of Echocardiography recommendations for use of echocardiography in clinical trials. *Journal of the American Society of Echocardiography*, **2004**, 17, 1086-119	5.8	392
81	Clinical, angiographic, and intravascular ultrasound characteristics of early saphenous vein graft failure. *Journal of the American College of Cardiology*, **2004**, 44, 53-6	15.1	31
80	Intravascular ultrasound assessment of angiographic filling defects in native coronary arteries: do they always contain thrombi?. *Journal of the American College of Cardiology*, **2004**, 44, 2087-9	15.1	13
79	Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. *Lancet, The*, **2004**, 364, 1519-21	40	1155
78	Impact of preinterventional arterial remodeling on neointimal hyperplasia after implantation of (non-polymer-encapsulated) paclitaxel-coated stents: a serial volumetric intravascular ultrasound analysis from the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). *Circulation*, **2003**, 108, 1295-8	16.7	33
77	Serial volumetric intravascular ultrasound assessment of native coronary artery versus saphenous vein grafts in-stent restenosis lesions after conventional catheter-based treatment. *American Journal of Cardiology*, **2003**, 91, 739-41	3	0

76	Usefulness of preprocedural coronary lesion morphology as assessed by intravascular ultrasound in predicting Thrombolysis In Myocardial Infarction frame count after percutaneous coronary intervention in patients with Q-wave acute myocardial infarction. *American Journal of Cardiology*, **2003**, 91, 870-2	3	6
75	Relation of plaque morphology to thrombolysis in myocardial infarction flow in acute myocardial infarction determined by intravascular ultrasound. *American Journal of Cardiology*, **2003**, 91, 1096-9	3	7
74	Multiple versus single coronary plaque ruptures detected by intravascular ultrasound in stable and unstable angina pectoris and in acute myocardial infarction. *American Journal of Cardiology*, **2003**, 91, 1333-5	3	32
73	Determinants of angiographically silent stenoses in patients with coronary artery disease. *American Journal of Cardiology*, **2003**, 91, 1335-8	3	4
72	Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade. *American Journal of Cardiology*, **2003**, 92, 728-32	3	39
71	Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. *American Journal of Cardiology*, **2003**, 92, 930-5	3	441
70	Incidence and mechanism of late stent malapposition after phosphorus-32 radioactive stent implantation. *American Journal of Cardiology*, **2003**, 92, 970-2	3	7
69	Impact of the acute results on the long-term outcome after the treatment of in-stent restenosis: a serial intravascular ultrasound study. *Catheterization and Cardiovascular Interventions*, **2003**, 60, 483-8	2.7	4
68	Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. *Journal of the American College of Cardiology*, **2003**, 41, 1721-4	15.1	347
67	Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. *Journal of the American Society of Echocardiography*, **2003**, 16, 777-802	5.8	3276
66	A paclitaxel-eluting stent for the prevention of coronary restenosis. *New England Journal of Medicine*, **2003**, 348, 1537-45	59.2	376
65	Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). *Circulation*, **2003**, 107, 517-20	16.7	161
64	Regional remodeling as the cause of late stent malapposition. *Circulation*, **2003**, 107, 2660-3	16.7	73
63	Intravascular ultrasound analysis of infarct-related and non-infarct-related arteries in patients who presented with an acute myocardial infarction. *Circulation*, **2003**, 107, 2889-93	16.7	164
62	Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. *Circulation*, **2003**, 108, 43-7	16.7	394
61	Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency. *American Journal of Cardiology*, **2002**, 89, 54-7	3	51
60	Analysis of stent edge restenosis with different forms of brachytherapy. *American Journal of Cardiology*, **2002**, 89, 322-5	3	5
59	Intravascular ultrasound assessment of spontaneous coronary artery dissection. *American Journal of Cardiology*, **2002**, 89, 466-8	3	167

58	Volumetric intravascular ultrasound quantification of the amount of atherosclerosis and calcium in nonstenotic arterial segments. *American Journal of Cardiology*, **2002**, 89, 757-60	3	43
57	Intravascular ultrasound findings in patients with acute coronary syndromes with and without elevated troponin I level. *American Journal of Cardiology*, **2002**, 89, 1111-3	3	9
56	Comparison of native coronary artery in-stent recurrence rates with longer versus shorter narrowings. *American Journal of Cardiology*, **2002**, 90, 422-5	3	
55	Intravascular ultrasound analysis of the impact of gamma radiation therapy on the treatment of saphenous vein graft in-stent restenosis. *American Journal of Cardiology*, **2002**, 90, 1378-81	3	1
54	Dose volume histogram assessment of late stent malapposition after intravascular brachytherapy. *Cardiovascular Radiation Medicine*, **2002**, 3, 190-2		7
53	Diet-drug valvulopathy. *ACC Current Journal Review*, **2002**, 11, 17-20		4
52	Incidence, morphology, angiographic findings, and outcomes of intramural hematomas after percutaneous coronary interventions: an intravascular ultrasound study. *Circulation*, **2002**, 105, 2037-42	16.7	75
51	Stroke complicating percutaneous coronary interventions: incidence, predictors, and prognostic implications. *Circulation*, **2002**, 106, 86-91	16.7	167
50	Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation*, **2002**, 105, 539-42	16.7	4322
49	Background incidence of late malapposition after bare-metal stent implantation. *Circulation*, **2002**, 106, 1753-5	16.7	87
48	Morphologic and angiographic features of coronary plaque rupture detected by intravascular ultrasound. *Journal of the American College of Cardiology*, **2002**, 40, 904-10	15.1	299
47	Testing the test: the reliability of echocardiography in the sequential assessment of valvular regurgitation. *American Heart Journal*, **2002**, 144, 115-21	4.9	31
46	Echocardiographic evaluation of pulmonary artery pressure with clinical correlates in predominantly obese adults. *Journal of the American Society of Echocardiography*, **2002**, 15, 454-62	5.8	25
45	Appetite suppressants and valvular heart disease. *American Journal of the Medical Sciences*, **2001**, 321, 285-91	2.2	34
44	Accelerated dobutamine stress testing: safety and feasibility in patients with known or suspected coronary artery disease. *Clinical Cardiology*, **2001**, 24, 141-5	3.3	10
43	Serial intravascular ultrasound analysis of edge recurrence after intracoronary gamma radiation treatment of native artery in-stent restenosis lesions. *American Journal of Cardiology*, **2001**, 87, 1145-9	3	16
42	Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population. *American Journal of Cardiology*, **2001**, 88, 248-52	3	43
41	An intravascular ultrasound classification of angiographic coronary artery aneurysms. *American Journal of Cardiology*, **2001**, 88, 365-70	3	76

40	Intravascular ultrasound assessment of the mechanism of lumen enlargement during cutting balloon angioplasty treatment of in-stent restenosis. *American Journal of Cardiology*, **2001**, 88, 1032-4	3	25
39	Comparison of luminal enlargement by direct coronary stenting versus predilation coronary stenting by three-dimensional volumetric intravascular ultrasound analysis. *American Journal of Cardiology*, **2001**, 88, 1179-82	3	16
38	Sex differences in morphology of coronary artery plaque assessed by intravascular ultrasound. *Coronary Artery Disease*, **2001**, 12, 17-20	1.4	8
37	Comparative efficacy of gamma-irradiation for treatment of in-stent restenosis in saphenous vein graft versus native coronary artery in-stent restenosis: An intravascular ultrasound study. *Circulation*, **2001**, 104, 3020-2	16.7	11
36	Serial intravascular ultrasound assessment of the efficacy of intracoronary gamma-radiation therapy for preventing recurrence in very long, diffuse, in-stent restenosis lesions. *Circulation*, **2001** , 104, 856-9	16.7	37
35	Intravascular ultrasound assessment of the mechanisms and results of brachytherapy. *Circulation*, **2001**, 104, 1320-5	16.7	48
34	Serial intravascular ultrasound analysis of the impact of lesion length on the efficacy of intracoronary gamma-irradiation for preventing recurrent in-stent restenosis. *Circulation*, **2001**, 103, 188-91	16.7	26
33	Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy. *Journal of Biological Chemistry*, **2001**, 276, 10039-48	5.4	69
32	Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. *Journal of the American College of Cardiology*, **2001**, 37, 1726-32	15.1	416
31	Specificity of Doppler echocardiography for the assessment of changes in valvular regurgitation: comparison of side-by-side versus serial interpretation. *Journal of the American College of Cardiology*, **2001**, 37, 1614-21	15.1	6
30	No evidence that 3 monthsPtreatment with fenfluramine increases risk of valvular regurgitation, although study may lack power to detect significant effect. *Evidence-based Cardiovascular Medicine*, **2001**, 5, 128-129		
29	The contribution of "mechanical" problems to in-stent restenosis: An intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. *American Heart Journal*, **2001**, 142, 970-4	4.9	85
28	Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine*, **2001**, 134, 267-73	8	28
27	Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin. *Journal of Physiology*, **2000**, 525 Pt 2, 483-98	3.9	85
26	Pathologic validation of a new method to quantify coronary calcific deposits in vivo using intravascular ultrasound. *American Journal of Cardiology*, **2000**, 85, 37-40	3	32
25	Assessment of coronary plaque with optical coherence tomography and high-frequency ultrasound. *American Journal of Cardiology*, **2000**, 85, 641-4	3	127
24	Serial volumetric intravascular ultrasound analysis of the efficacy of beta irradiation in preventing recurrent in-stent restenosis. *American Journal of Cardiology*, **2000**, 85, 651-3, A10	3	12
23	Effect of preintervention plaque burden on subsequent intimal hyperplasia in stented coronary artery lesions. *American Journal of Cardiology*, **2000**, 86, 1318-21	3	27

22	Safety of intracoronary gamma-radiation on uninjured reference segments during the first 6 months after treatment of in-stent restenosis: a serial intravascular ultrasound study. *Circulation*, **2000**, 101, 2227-30	16.7	20
21	Mechanism of lumen enlargement during intracoronary stent implantation: an intravascular ultrasound study. *Circulation*, **2000**, 102, 7-10	16.7	85
20	Effect of intracoronary gamma-radiation therapy on in-stent restenosis: An intravascular ultrasound analysis from the gamma-1 study. *Circulation*, **2000**, 102, 2915-8	16.7	49
19	Positive remodeling, regression of in-stent neointimal hyperplasia, and late stent malapposition in the absence of brachytherapy. *Circulation*, **2000**, 102, E111	16.7	3
18	Sex differences in coronary artery size assessed by intravascular ultrasound. *American Heart Journal* , **2000**, 139, 649-53	4.9	164
17	Natural history of intravascular ultrasound-detected edge dissections from coronary stent deployment. *American Heart Journal*, **2000**, 139, 59-63	4.9	56
16	Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia. *American Heart Journal*, **2000**, 139, 1061-70	4.9	29
15	Intravascular ultrasonic analysis of plaque characteristics associated with coronary artery remodeling. *American Journal of Cardiology*, **1999**, 84, 37-40	3	51
14	Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. *Journal of the American College of Cardiology*, **1999**, 34, 2088-95	15.1	24
13	Update on Intravascular Ultrasound. *Journal of Interventional Cardiology*, **1998**, 11, S83-S86	1.8	1
12	Effect of atenolol or metoprolol on arbutamine stress echocardiography in patients suspected of having coronary artery disease. *American Journal of Cardiology*, **1998**, 82, 830-2, A10	3	
11	An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. *New England Journal of Medicine*, **1998**, 339, 725-32	59.2	201
10	Effects of prolonging peak dobutamine dose during stress echocardiography. *Journal of the American College of Cardiology*, **1997**, 29, 526-30	15.1	18
9	Effect of beta-blockade on dobutamine stress echocardiography. *American Heart Journal*, **1996**, 131, 698-703	4.9	18
8	Factors influencing regional myocardial contractile response to inotropic stimulation. Analysis in humans with stable ischemic heart disease. *Circulation*, **1996**, 94, 643-50	16.7	26
7	Effect of hydration on cavity obliteration during dobutamine stress echocardiography. *Clinical Cardiology*, **1995**, 18, 17-20	3.3	13
6	Development of coronary compensatory enlargement in vivo: sequential assessments with intravascular ultrasound. *American Heart Journal*, **1995**, 130, 1283-5	4.9	14
5	Dynamic expansion of the coronary arteries: implications for intravascular ultrasound measurements. *American Heart Journal*, **1995**, 130, 46-51	4.9	35

4	Three-dimensional intravascular ultrasound assessment of plaque volume after successful atherectomy. *American Heart Journal*, **1995**, 130, 413-9	4.9	25
3	Effect of beta-adrenergic receptor blockade on the physiologic response to dobutamine stress echocardiography. *American Heart Journal*, **1995**, 130, 248-53	4.9	21
2	Optimal stage duration in dobutamine stress echocardiography. *Journal of the American College of Cardiology*, **1995**, 25, 605-9	15.1	26
1	In vivo assessment by intravascular ultrasound of enlargement in saphenous vein bypass grafts. *American Journal of Cardiology*, **1995**, 76, 1066-9	3	25